Vision RT celebrates 3,000 systems in clinical use worldwide

Founded in 2001 with a mission to make radiation therapy more effective for cancer patients, Vision RT invented Surface Guided Radiation Therapy and remains the market leader in the field.

Today, Vision RT proudly celebrates a significant milestone: more than 3,000 of our systems are actively used in clinics worldwide.

« At Vision RT, we take immense pride in knowing that every SGRT system we develop and deliver represents a step forward in improving cancer care,” said Dr. Norman Smith, CEO.  « Achieving this milestone is a testament to the transformative impact we’ve made with our technology setting a new standard in radiotherapy. Our ultimate goal is for every clinic and every patient around the world to have access to our technology. »

Since the installation of our very first clinical system at Massachusetts General Hospital back in 2004, Vision RT’s SGRT solutions have become a critical part of the new standard of care for radiation therapy. Our systems are in 24 of the top 25 “Best Hospitals for Cancer,” as ranked by U.S. News & World Report.

—

About Vision RT:

Vision RT is the inventor of Surface Guided Radiation Therapy (SGRT) which uses camera systems to track surface data, to offer more guidance across every step of the radiotherapy workflow: simulation, planning, treatment and dose visualisation.

We work tirelessly to improve the accuracy, efficiency, safety and comfort of radiation therapy.

Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in WDI employ more than 21,000 people.